MacroGenics (MGNX)
(Delayed Data from NSDQ)
$4.55 USD
-0.08 (-1.73%)
Updated May 24, 2024 04:00 PM ET
After-Market: $4.56 +0.01 (0.22%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 221 - 240 ( 361 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
1Q, Well Financed to Unlock Value from Diverse Pipeline, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Healthcare - Cancer in Washington: 2017 AACR Highlights
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: MacroGenics, Inc.
Industry: Medical - Products
Healthcare - Cancer in Washington: 2017 AACR Highlights
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: MacroGenics, Inc.
Industry: Medical - Products
4Q/FY16, Incremental Updates to Large Pipeline, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
4Q16 Clinical Progress on Multiple Fronts
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: MacroGenics, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Sustained Tumor Reductions Seen for Enoblituzumab; New Pipeline Programs Display Multiple
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
R-D Day Update Emphasizes Combination Immunotherapy; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
We are transferring coverage to Mark Breidenbach and reestablishing estimates, a Buy rating and $40 target
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: MacroGenics, Inc.
Industry: Medical - Products
3Q, Continued Pipeline Expansion Provides MGNX with Additional Shots on Goal, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
EPS, MGNX Shows a Profit Due to JNJ Deal, Next 6-18 Months should be Data Rich, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences: Upcoming Events for the Week of August 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Licenses Second Preclinical DART to J-J, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D